Overview

Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers

Status:
Completed

Trial end date:
2019-04-20

Target enrollment:

Participant gender:

Summary

This study is an open-label, randomized, fasted, single dose, crossover study to evaluate the bioequivalence of Chong Kun Dang Pharmaceutical "Chong Kun Dang Tofacitinib Tablet" and Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in healthy volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Treatments:

Tofacitinib